Wave Life Sciences Secures FDA Alignment for Streamlined WVE-006 Trial in AATD
Event summary
- Wave Life Sciences plans a single, two-year registrational trial for WVE-006 with a one-year interim analysis for potential accelerated approval.
- FDA supports the use of Wave’s LC-MS assay to measure M-AAT and Z-AAT proteins for the WVE-006 program.
- WVE-006 is designed to address both lung and liver manifestations of AATD with infrequent subcutaneous dosing.
- The ongoing Phase 1b/2a RestorAATion-2 trial data for the 600 mg (monthly) multidose cohort is expected in Q4 2026.
The big picture
Wave Life Sciences’ alignment with the FDA on the registrational pathway for WVE-006 underscores the growing interest in RNA editing therapies for rare genetic disorders. The streamlined trial design could set a precedent for other biotech companies developing similar treatments, potentially reducing the time and cost of bringing innovative therapies to market. The focus on AATD, a condition with significant unmet medical needs, highlights the strategic importance of targeting rare diseases with high-impact therapies.
What we're watching
- Regulatory Efficiency
- Whether the streamlined trial design will accelerate WVE-006’s path to market and reduce development costs.
- Clinical Efficacy
- The pace at which interim data from the RestorAATion-2 trial will demonstrate WVE-006’s safety and efficacy.
- Market Potential
- How WVE-006’s potential to address both lung and liver manifestations of AATD will position it against existing therapies.
Related topics
